Aquavit Pharmaceuticals develops drugs, biologics and devices built around proprietary microchannel delivery — placing a therapy in the precise layer of tissue where it acts, at a dose the clinician chooses. Headquartered in New York, operating since 2010.
Science personalized. Healthcare modernized.
Most companies choose a molecule and then ask how to deliver it. Aquavit began at the other end.
The outermost layer of skin excludes almost anything above roughly 500 daltons. Crossing it reliably changes what can be treated, at what dose, and by whom — and that is the problem the company was built to solve.
From it came a patented microchannel geometry, formulations built to travel through it, and APOLLO™ — a smart desktop compounding device that lets a clinician personalize treatment in the room rather than accept one fixed at a factory.
Programs run across neuroscience, oncology, medical dermatology, medical aesthetics and immunology. Full detail is on the company's own site: aquavitpharma.com.
AQT-001 — the world's first microchannel mesotherapy™ device™, in commercial use by physicians worldwide.
The Personalized Injection Treatment Optimizer, carried as program PITO-001 — smart desktop compounding, granted internationally, including the United States, Europe and Korea.
A botulinum toxin type A approved in more than eight countries outside the United States, licensed by Aquavit for the United States and Canada, with two INDs cleared in 2023.
AQT-004 and AQB-121 — combination products pairing microchannel delivery with botulinum toxin. Fixed-depth placement, controlled across a broad application area. In development.
An oncology program for actinic keratosis and basal cell carcinoma.
A single-use epidermal device for self-administered vaccines and biologics.
